General Information of Drug (ID: DMKEPGN)

Drug Name
PT-319
Synonyms
149485-99-4; Thiourea, N-(2-(3-methoxyphenyl)ethyl)-N'-2-thiazolyl-; PETT Analog 6; Thiourea, N-[2-(3-methoxyphenyl)ethyl]-N'-2-thiazolyl-; PT-319; AC1MHDMC; SCHEMBL6963302; BDBM1899; CHEMBL400733; DTXSID80164295; ZINC13744847; AKOS030030940; 1-(2-Thiazolyl)-3-[3-methoxyphenethyl]thiourea; N-(2-(3-Methoxyphenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(3-methoxyphenyl)ethyl]-3-thiazol-2-yl-thiourea; 1-[2-(3-methoxyphenyl)ethyl]-3-1,3-thiazol-2-ylthiourea
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 293.4
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C13H15N3OS2
IUPAC Name
1-[2-(3-methoxyphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
Canonical SMILES
COC1=CC=CC(=C1)CCNC(=S)NC2=NC=CS2
InChI
InChI=1S/C13H15N3OS2/c1-17-11-4-2-3-10(9-11)5-6-14-12(18)16-13-15-7-8-19-13/h2-4,7-9H,5-6H2,1H3,(H2,14,15,16,18)
InChIKey
TXUPZNCSUKFSFG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3001165
CAS Number
149485-99-4
TTD ID
D0A9WC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
2 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
3 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
4 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
7 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
8 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.